circle-image

Short

Trend Resistance

Uptrend Above: 24350

Bull Signal Above: 24410
circle-image

Term

Trend Point Acts

Trend Point: 24330

My PCR: 1.02
44 Range 126

Up Trend Signal

circle-image

View

Trend Suport

Down Below: 24310

Bear Signal Below: 24240
Short Term View Historic Data

Nifty View On: Monday 17 Aug 2026

Day Close

24366
Day High

24405
Day Low

24296
Day Avg

24356
14 Aug 2026
5 SMA

24450
10 SMA

24547
20 SMA

24323
50 SMA

24084
200 SMA

24730
5 EMA

24406
10 EMA

24454
20 EMA

24335
50 EMA

24215
Monday View
Resist 2

24480
Resist 1

24420
Mid Point

24370
Suport 1

24310
Suport 2

24260
52W High

26373
52w Low

22182
52w Down

7.61%
52w Up

9.85%
Panic View
Resist 2

24580
Resist 1

24500
Mid Point

24370
Suport 1

24230
Suport 2

24150
5d High

24620
5d Low

24265
10d High

24774
10d Low

24265
Days High & Low 20d High

24774
20d Low

23606
50d High

24774
50d Low

23070
All Avg

24269
FFTH

24553
FTTL

24435
TTTH

24604
TTTL

24215
High & Low Avg TTFH

24385
TFFL

23817
High Avg

24514
Low Avg

24156
All Avg

24335
Nifty Historic Prediction Data

Nifty Last Five Days Moves

SNo. Date Day Close Day High Day Low 5 DMA 10 DMA 20 DMA 50 DMA 200 DMA
1 14 Aug 2026 24366 24405 24296 24450 24547 24323 24084 24730
2 13 Aug 2026 24395 24431 24311 24491 24549 24321 24065 24738
3 12 Aug 2026 24435 24473 24265 24539 24541 24305 24045 24745
4 11 Aug 2026 24471 24576 24429 24577 24522 24287 24026 24752
5 10 Aug 2026 24583 24620 24511 24605 24474 24266 24004 24758
Nifty Historic Data And Moving Avg

Go Back

Innova Captab Ltd is an integrated pharmaceutical company in India with a presence across the pha...

Posted: 03 Nov 2024

Innova Captab Ltd is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Since our inception in 2006 with a small base, we have grown strength to strength and for last more than 15 years, we are catering to top Indian pharmaceuticals companies including 10 of the top 10, and 14 of the top 15. We have license to manufacture products through two state of the art manufacturing facilities while maintaining WHO-GMP, EU-GMP and other major registrations. With the support of our world class manufacturing facilities and a reliable supply value chain, we are continuously thriving to maintain highly efficient operations. The foundation of our Company is our in-house research and development (R&D). which helps to focus on to build an increasingly complex product portfolio and attract and retain customers. We proudly possess a strong team of 1000+ employees. As a responsible corporate entity, we are been continuously endeavouring to comply with Environmental, Social & Governance compliance requirements covering the aspects of Legal compliance, ethics & business conduct, quality & patient safety, human rights, labour and employment, health safety and well-being of employees, sustainability & environmental responsibility, quality management system. Our business includes CDMO business providing research, product development and manufacturing services. We were third fastest growing CDMO in terms of Operating Income over the period Fiscal 2019 to Fiscal 2023 and positioned our Company to benefit from the growth in the CDMO market by developing strong R&D and manufacturing operations for our customers to support their domestic sales and exports to certain markets. Fourteen of the top fifteen Indian pharmaceutical companies that CRISIL Research identified as the largest players in the domestic formulation market in Fiscal 2023 have been a part of our customer base. Our Capabilities World class manufacturing facilities in Baddi, Himachal Pradesh and Our manufacturing facilities have good manufacturing practices certifications in conformity with the format recommended by WHO-GMP, EU-GMP and many other international authorities. Strong R&D focus to build an increasingly complex product portfolio and attract and retain customers Our CDMO product portfolio spans across both acute and chronic therapeutic areas Leading presence and one of the fastest growing CDMOs in the Indian pharmaceutical formulations market Well established relationships with our marquee CDMO customer base Our strength in CDMO sphere includes: Our comprehensive CDMO formulation capabilities allow us to offer our customers multiple dosage forms, including oral solids, oral liquids, dry syrups and injectables, as well as more complex delivery forms such as modified and sustained release forms and tablets in capsules. We manufacture products that are in all the top ten therapeutic areas by sales in the Indian formulation market in Fiscal 2023 as identified by CRISIL Research. We manufacture products across some of the key therapeutic areas. Our operational track record in successful delivery of products, R&D, quality and technical standards and productivity Strong R&D and manufacturing operations for our customers to support their domestic sales and exports to certain markets. Our R&D laboratory is equipped with the entire suite of necessary equipment for the development of solid oral and liquid dosage forms Domestic Branded Generics Our Branded Generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under our own brand names through online and offline channels. Our branded generic products are generic medicines for which the patents have expired, that are sold directly to our distributors, stockists & retailers. We sell our domestic branded generic products through our pan-Indian network of distributors, stockists and pharmacies. Our generic drug products are also available online through various e-commerce pharmacy sites. We have developed a diversified branded generics product portfolio including Tablets, capsules, dry syrups, dry powder injection, ointments and liquid orals

Market Bits

"In investing, what is comfortable is rarely profitable." — Robert Arnott

Be prepared to invest in a down market and to "get out" in a soaring market, as per the philosophy of Warren Buffett.